Javascript must be enabled to continue!
<b>Multitarget-Directed Multiple Ligands in Anti-VEGF Resistant Glioblastoma Therapeutics: An in Silico Approach to Identify Potential Phytochemicals</b>
View through CrossRef
Angiogenesis is an important process in tumor progression. Vascular endothelial growth factor (VEGF) is the key factor regulating angiogenesis, and hence, anti-VEGF therapy is considered a useful therapeutic approach in tumor conditions. However, the drug resistance and lack of efficacy of existing drugs limit the potential of such a therapeutic approach in certain cases, and the tumor growth will continue through alternative mechanisms. Glioblastoma (GBM) is one such type of tumor that shows resistance to anti-VEGF therapy. Previously, we identified the hub genes differentially expressed in anti-VEGF resistance in GBM. Medhya Rasayana, an Ayurvedic formulation, is used for the management of neurological disorders. In the present study, we used computational docking methods to identify the phytochemicals present in the medicinal plants of Medhya Rasayana, which can target the proteins expressed by the hub genes associated with anti-VEGF resistance. Network pharmacological analysis was also performed to identify the highly effective phytochemicals for a possible adjuvant therapy. Results showed that multiple phytochemicals of Glycirrhiza glabra Linn, Evolvulus alsinoides, and Celastrus paniculatus target the anti-VGEF resistant proteins in GBM. This indicates the multi-targeting property of phytocompounds of Medhya Rasayana plants, which may be considered for adjuvant therapy along with anti-VEGF therapy.
Received: 10 July 2024 | Revised: 11 October 2024 | Accepted: 6 January 2025
Conflicts of Interest
The authors declare that they have no conflicts of interest to this work.
Data Availability Statement
The data that support this work are available upon reasonable request to the corresponding author.
Author Contribution Statement
Kesavan R. Arya: Methodology, Formal analysis, Investigation, Writing - original draft, Writing - review & editing, Visualization, Funding acquisition. Sasikumar J. Soumya: Methodology, Formal analysis, Investigation, Writing - original draft, Writing - review & editing,Visualization, Funding acquisition. Anuroopa G. Nadh: Formal analysis, Investigation, Funding acquisition. Thankamani R. Aswathy: Formal analysis, Investigation. Vijayalakshmi B.: Investigation. Achuthsankar S. Nair: Resources, Project administration. Oommen V. Oommen: Validation, Resources, Writing - review & editing, Project administration. Perumana R. Sudhakaran: Conceptualization, Methodology, Validation, Investigation, Resources, Writing - review & editing, Project administration, Funding acquisition.
Title: <b>Multitarget-Directed Multiple Ligands in Anti-VEGF Resistant Glioblastoma Therapeutics: An in Silico Approach to Identify Potential Phytochemicals</b>
Description:
Angiogenesis is an important process in tumor progression.
Vascular endothelial growth factor (VEGF) is the key factor regulating angiogenesis, and hence, anti-VEGF therapy is considered a useful therapeutic approach in tumor conditions.
However, the drug resistance and lack of efficacy of existing drugs limit the potential of such a therapeutic approach in certain cases, and the tumor growth will continue through alternative mechanisms.
Glioblastoma (GBM) is one such type of tumor that shows resistance to anti-VEGF therapy.
Previously, we identified the hub genes differentially expressed in anti-VEGF resistance in GBM.
Medhya Rasayana, an Ayurvedic formulation, is used for the management of neurological disorders.
In the present study, we used computational docking methods to identify the phytochemicals present in the medicinal plants of Medhya Rasayana, which can target the proteins expressed by the hub genes associated with anti-VEGF resistance.
Network pharmacological analysis was also performed to identify the highly effective phytochemicals for a possible adjuvant therapy.
Results showed that multiple phytochemicals of Glycirrhiza glabra Linn, Evolvulus alsinoides, and Celastrus paniculatus target the anti-VGEF resistant proteins in GBM.
This indicates the multi-targeting property of phytocompounds of Medhya Rasayana plants, which may be considered for adjuvant therapy along with anti-VEGF therapy.
Received: 10 July 2024 | Revised: 11 October 2024 | Accepted: 6 January 2025
Conflicts of Interest
The authors declare that they have no conflicts of interest to this work.
Data Availability Statement
The data that support this work are available upon reasonable request to the corresponding author.
Author Contribution Statement
Kesavan R.
Arya: Methodology, Formal analysis, Investigation, Writing - original draft, Writing - review & editing, Visualization, Funding acquisition.
Sasikumar J.
Soumya: Methodology, Formal analysis, Investigation, Writing - original draft, Writing - review & editing,Visualization, Funding acquisition.
Anuroopa G.
Nadh: Formal analysis, Investigation, Funding acquisition.
Thankamani R.
Aswathy: Formal analysis, Investigation.
Vijayalakshmi B.
: Investigation.
Achuthsankar S.
Nair: Resources, Project administration.
Oommen V.
Oommen: Validation, Resources, Writing - review & editing, Project administration.
Perumana R.
Sudhakaran: Conceptualization, Methodology, Validation, Investigation, Resources, Writing - review & editing, Project administration, Funding acquisition.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Refractive status and ocular characteristics of preschool children with retinopathy of prematurity after different treatments
Refractive status and ocular characteristics of preschool children with retinopathy of prematurity after different treatments
AIM: To compare the changes in preschool refractive status, ocular biological parameters, and higher-order aberrations in children with retinopathy of prematurity (ROP) after retin...
Investigating the role of the apelinergic system in glioblastoma
Investigating the role of the apelinergic system in glioblastoma
<p>Elucidating the molecular signalling circuitry that underpins the pathogenesis of cancers is critical to understanding and developing effective treatment paradigms for can...
Molecular Analysis of Vascular Endothelial Growth Factor (VEGF) Receptors in EUS-guided Samples Obtained from Patients with Pancreatic Adenocarcinoma*
Molecular Analysis of Vascular Endothelial Growth Factor (VEGF) Receptors in EUS-guided Samples Obtained from Patients with Pancreatic Adenocarcinoma*
Background & Aims: Vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1 and VEGF-R2) are the most important angiogenesis stimulating factors in pancreatic cance...
The correlation of MMP-9 and VEGF expressions towards nasopharyngeal angiofibroma clinical stage
The correlation of MMP-9 and VEGF expressions towards nasopharyngeal angiofibroma clinical stage
ABSTRACTBackground: Nasopharyngeal angiofibroma (NA) is a benign tumor with a destructive tendency, commonly affecting male adolescents. The management of NA could become quite a c...

